

Special Issue

Interstitial Lung Diseases: Focus on Pleuroparenchymal Fibroelastosis

Message from the Guest Editor

The term "interstitial lung diseases" (ILDs) includes a wide spectrum of heterogeneous entities with different prognoses and treatment options. Pleuroparenchymal fibroelastosis (PPFE) is a specific clinicopathologic entity that affects the visceral pleura and the subpleural parenchyma with an upper-lobe predilection, characterized by elastic intra-alveolar fibrosis and scattered fibroblastic foci. Its pathogenesis is still unclear, but the heterogeneous spectrum of clinical presentations and behavior suggests that it may represent the final expression of a variable interplay between immune dysregulation, environmental exposure, and genetic predisposition. PPFE can present as an idiopathic form or in association with a variety of different conditions, including infections, lung and bone marrow transplantation, and autoimmune diseases. The main goals of this Special Issue are to update and summarize insights and challenges of PPFE, and leaders in the different fields will be invited to provide comprehensive reviews on interstitial lung disease topics.

Guest Editor

Dr. Martina Bonifazi

Department of Biomedical Sciences and Public Health, Università Politecnica delle Marche, Ancona, Italy

Deadline for manuscript submissions

closed (30 June 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/117202

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).